Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120184) titled 'A Single-Center, Single-Arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Combined with TP Regimen as Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma' on March 10.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Jiangsu Cancer Hospital

Condition: Esophageal squamous cell carcinoma

Recruitment Status: Recruiting

Phase: 4

Date of First Enrollment: 2026-03-10

Target Sample Size: Experimental arm :33;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=311232

Disclaimer: Curated by HT Syndication....